MINIject

iSTAR Medical Shows Initial Positive Progress of US STAR-V Trial for MINIject

Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US. Positive feedback from world-leading glaucoma surgeons involved in the trial. MINIject is the only commercially available MIGS device targeting the supraciliary space. Commercial rollout continues following European approval in 2021

iSTAR Medical Receives European Market Approval for Glaucoma Implant MINIject

MINIject is currently being investigated in iSTAR Medical’s pivotal STAR-V study, which was approved by the United States Food and Drug Administration (FDA) in July 2021,

iSTAR Medical Receives U.S. FDA Approval to Commence Pivotal Trial for MINIject in Glaucoma Patients

The STAR-V trial evaluates MINIject’s efficacy by the mean reduction in eye pressure, as well as the proportion of patients achieving at least a 20 percent reduction in eye pressure notes iSTAR Medical.
- Advertisement -spot_img

Latest News

ExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization Technology

The funding will accelerate candidate selection for preclinical studies and develop a pipeline of protein-based therapeutics. The primary focus for the pipeline will be recombinant proteins that have historically faced production and manufacturing challenges based on current technology notes ExpressionEdits.
- Advertisement -spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy